TVTX.NASDAQTravere Therapeutics, INC
Form 4: Travere Therapeutics Executive Sells Shares
Sentiment:
Insider Transaction (Form 4)
Peter Heerma, EVP, CHIEF COMMERCIAL OFFICER of Travere Therapeutics, Inc., sold 283,189 shares of common stock on September 15, 2026.
Summary
- Option exercise/conversion: acquired 39,283 Common Stock at $26.88 ($1,055,927) on September 15, 2026; holds 181,349 after (Direct).
- Option exercise/conversion: acquired 1,381 Common Stock at $22.40 ($30,934) on September 15, 2026; holds 182,730 after (Direct).
- Option exercise/conversion: acquired 36,526 Common Stock at $8.93 ($326,177) on September 15, 2026; holds 219,256 after (Direct).
- Open-market sale: disposed of 71,938 Common Stock at $62.05 ($4,463,875) on September 15, 2026; holds 147,318 after (Direct).
- Open-market sale: disposed of 27,421 Common Stock at $62.59 ($1,716,379) on September 15, 2026; holds 119,897 after (Direct).
- Open-market sale: disposed of 1,400 Common Stock at $63.65 ($89,113) on September 15, 2026; holds 118,497 after (Direct).
- Open-market sale: disposed of 1,431 Common Stock at $65.31 ($93,458) on September 15, 2026; holds 117,066 after (Direct).
- Option exercise/conversion: acquired 100,000 Common Stock at $11.25 ($1,125,000) on September 16, 2026; holds 217,066 after (Direct).
- Option exercise/conversion: acquired 55,000 Common Stock at $15.46 ($850,300) on September 16, 2026; holds 272,066 after (Direct).
- Option exercise/conversion: acquired 17,717 Common Stock at $26.88 ($476,233) on September 16, 2026; holds 289,783 after (Direct).
- Open-market sale: disposed of 93,604 Common Stock at $63.25 ($5,920,182) on September 16, 2026; holds 196,179 after (Direct).
- Open-market sale: disposed of 79,113 Common Stock at $63.65 ($5,035,906) on September 16, 2026; holds 117,066 after (Direct).
- Option exercise/conversion: acquired 8,282 Common Stock at $22.40 ($185,517) on September 17, 2026; holds 125,348 after (Direct).
- Open-market sale: disposed of 8,282 Common Stock at $65.07 ($538,917) on September 17, 2026; holds 117,066 after (Direct).
- Option exercise/conversion: disposed of 39,283 Employee stock option (right to buy) on September 15, 2026; holds 18,217 after (Direct).
- Option exercise/conversion: disposed of 1,381 Employee stock option (right to buy) on September 15, 2026; holds 53,119 after (Direct).
- Option exercise/conversion: disposed of 36,526 Employee stock option (right to buy) on September 15, 2026; holds 28,474 after (Direct).
- Option exercise/conversion: disposed of 100,000 Employee stock option (right to buy) on September 16, 2026 (Direct).
- Option exercise/conversion: disposed of 55,000 Employee stock option (right to buy) on September 16, 2026 (Direct).
- Option exercise/conversion: disposed of 17,717 Employee stock option (right to buy) on September 16, 2026; holds 500 after (Direct).
- Option exercise/conversion: disposed of 8,282 Employee stock option (right to buy) on September 17, 2026; holds 44,837 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $17,857,830 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Peter Heerma — Officer (EVP, CHIEF COMMERCIAL OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Option exercise/conversion | Common Stock | 39,283 | $27 | $1.1M | 181,349 |
| 2026-09-15 | Option exercise/conversion | Common Stock | 1,381 | $22 | $30.9K | 182,730 |
| 2026-09-15 | Option exercise/conversion | Common Stock | 36,526 | $9 | $326.2K | 219,256 |
| 2026-09-15 | Open-market sale | Common Stock | 71,938 | $62 | $4.5M | 147,318 |
| 2026-09-15 | Open-market sale | Common Stock | 27,421 | $63 | $1.7M | 119,897 |
| 2026-09-15 | Open-market sale | Common Stock | 1,400 | $64 | $89.1K | 118,497 |
| 2026-09-15 | Open-market sale | Common Stock | 1,431 | $65 | $93.5K | 117,066 |
| 2026-09-16 | Option exercise/conversion | Common Stock | 100,000 | $11 | $1.1M | 217,066 |
| 2026-09-16 | Option exercise/conversion | Common Stock | 55,000 | $15 | $850.3K | 272,066 |
| 2026-09-16 | Option exercise/conversion | Common Stock | 17,717 | $27 | $476.2K | 289,783 |
| 2026-09-16 | Open-market sale | Common Stock | 93,604 | $63 | $5.9M | 196,179 |
| 2026-09-16 | Open-market sale | Common Stock | 79,113 | $64 | $5.0M | 117,066 |
| 2026-09-17 | Option exercise/conversion | Common Stock | 8,282 | $22 | $185.5K | 125,348 |
| 2026-09-17 | Open-market sale | Common Stock | 8,282 | $65 | $538.9K | 117,066 |
| 2026-09-15 | Option exercise/conversion | Employee stock option (right to buy) | 39,283 | — | — | 18,217 |
| 2026-09-15 | Option exercise/conversion | Employee stock option (right to buy) | 1,381 | — | — | 53,119 |
| 2026-09-15 | Option exercise/conversion | Employee stock option (right to buy) | 36,526 | — | — | 28,474 |
| 2026-09-16 | Option exercise/conversion | Employee stock option (right to buy) | 100,000 | — | — | 0 |
| 2026-09-16 | Option exercise/conversion | Employee stock option (right to buy) | 55,000 | — | — | 0 |
| 2026-09-16 | Option exercise/conversion | Employee stock option (right to buy) | 17,717 | — | — | 500 |
| 2026-09-17 | Option exercise/conversion | Employee stock option (right to buy) | 8,282 | — | — | 44,837 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Option exercise/conversion (39,283 shares) |
| 2026-09-15 | Option exercise/conversion (1,381 shares) |
| 2026-09-15 | Option exercise/conversion (36,526 shares) |
| 2026-09-15 | Open-market sale (71,938 shares) |
| 2026-09-15 | Open-market sale (27,421 shares) |
| 2026-09-15 | Open-market sale (1,400 shares) |
| 2026-09-15 | Open-market sale (1,431 shares) |
| 2026-09-16 | Option exercise/conversion (100,000 shares) |
| 2026-09-16 | Option exercise/conversion (55,000 shares) |
| 2026-09-16 | Option exercise/conversion (17,717 shares) |
| 2026-09-16 | Open-market sale (93,604 shares) |
| 2026-09-16 | Open-market sale (79,113 shares) |
| 2026-09-17 | Option exercise/conversion (8,282 shares) |
| 2026-09-17 | Open-market sale (8,282 shares) |
| 2026-09-15 | Option exercise/conversion (39,283 shares) |
| 2026-09-15 | Option exercise/conversion (1,381 shares) |
| 2026-09-15 | Option exercise/conversion (36,526 shares) |
| 2026-09-16 | Option exercise/conversion (100,000 shares) |
| 2026-09-16 | Option exercise/conversion (55,000 shares) |
| 2026-09-16 | Option exercise/conversion (17,717 shares) |
| 2026-09-17 | Option exercise/conversion (8,282 shares) |
Keywords
insider transaction, Form 4, TVTX, Travere Therapeutics, Inc., bearish, Peter Heerma
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.